Wedbush Weighs in on argenx SE’s Q2 2024 Earnings (NASDAQ:ARGX)

argenx SE (NASDAQ:ARGX) – Investment analysts at Wedbush lowered their Q2 2024 earnings per share (EPS) estimates for argenx in a research report issued to clients and investors on Sunday, June 23rd. Wedbush analyst D. Nierengarten now anticipates that the company will earn ($1.67) per share for the quarter, down from their prior estimate of ($1.29). Wedbush has a “Outperform” rating and a $519.00 price objective on the stock. The consensus estimate for argenx’s current full-year earnings is ($2.89) per share. Wedbush also issued estimates for argenx’s Q3 2024 earnings at ($1.58) EPS, Q4 2024 earnings at ($1.34) EPS, FY2024 earnings at ($5.63) EPS, Q1 2025 earnings at ($0.63) EPS, Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at $0.20 EPS, FY2025 earnings at ($0.83) EPS, FY2026 earnings at $9.92 EPS and FY2027 earnings at $28.75 EPS.

argenx (NASDAQ:ARGX) last announced its earnings results on Monday, May 13th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.33). The business had revenue of $412.51 million for the quarter, compared to analysts’ expectations of $404.03 million. argenx had a negative net margin of 22.58% and a negative return on equity of 14.14%. During the same quarter last year, the business earned ($0.52) EPS.

Other research analysts also recently issued research reports about the stock. Robert W. Baird reduced their price target on shares of argenx from $505.00 to $490.00 and set an “outperform” rating for the company in a research report on Friday, March 1st. HC Wainwright reissued a “buy” rating and set a $448.00 target price on shares of argenx in a report on Monday. Wells Fargo & Company lifted their price target on argenx from $478.00 to $542.00 and gave the stock an “overweight” rating in a research note on Monday. Piper Sandler increased their price objective on argenx from $522.00 to $535.00 and gave the company an “overweight” rating in a research note on Monday. Finally, Truist Financial raised their price objective on argenx from $440.00 to $480.00 and gave the company a “buy” rating in a report on Tuesday. Five equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $525.42.

argenx Stock Down 1.3 %

ARGX opened at $445.88 on Wednesday. The firm’s fifty day simple moving average is $379.85 and its two-hundred day simple moving average is $386.89. argenx has a 52-week low of $327.73 and a 52-week high of $550.76. The company has a market cap of $26.50 billion, a price-to-earnings ratio of -78.78 and a beta of 0.65.

Institutional Investors Weigh In On argenx

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Parkside Financial Bank & Trust acquired a new position in shares of argenx in the 3rd quarter valued at $28,000. GAMMA Investing LLC raised its holdings in argenx by 420.0% in the 1st quarter. GAMMA Investing LLC now owns 78 shares of the company’s stock valued at $31,000 after buying an additional 63 shares during the period. FNY Investment Advisers LLC acquired a new position in argenx in the fourth quarter valued at about $38,000. Mather Group LLC. acquired a new stake in shares of argenx during the first quarter valued at about $38,000. Finally, Benjamin F. Edwards & Company Inc. purchased a new stake in shares of argenx in the 4th quarter valued at approximately $60,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.